AR003002A1 - Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones - Google Patents
Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposicionesInfo
- Publication number
- AR003002A1 AR003002A1 ARP960102931A AR10293196A AR003002A1 AR 003002 A1 AR003002 A1 AR 003002A1 AR P960102931 A ARP960102931 A AR P960102931A AR 10293196 A AR10293196 A AR 10293196A AR 003002 A1 AR003002 A1 AR 003002A1
- Authority
- AR
- Argentina
- Prior art keywords
- reduce
- compositions
- formula
- pharmaceutical compositions
- steroids
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229940124325 anabolic agent Drugs 0.000 abstract 1
- 239000003263 anabolic agent Substances 0.000 abstract 1
- -1 dimethylamino, diethylamino Chemical group 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se describen composiciones farmacéuticas que comprenden como agente activo compuestos de la fórmula (I), donde R es -CH2CON(CH3)-n-CH2-CH2CH2CH3 óSO(CH2)3CF2CF3 o una sal concurrente o secuencial, con cantidades efectivas de compuestos de fórmula( II), donde cada R1 es -H, -OH, -O(C1-C4)alquilo,-OCOC6H5, -OCO(C1-C6 alquilo), ó -OSO2(C4-C6 alquilo) y R2 es 1-piperidinilo, 1-pirrolidinilo, metil-1-pirrolidinilo dimetil-1-pirrolidinilo, 4-morfolino,dimetilamino, dietilamino ó1-hexametilenoimin o. Se presenta además el uso de un compuesto de la fórmula (I) en combinación con un compuesto de la fórmula(II), para reducir al mínimo las pérdidas óseas administrando en forma concurrente o secuencial un agenteanabólico ósea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47111195A | 1995-06-06 | 1995-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003002A1 true AR003002A1 (es) | 1998-05-27 |
Family
ID=23870302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102930A AR003134A1 (es) | 1995-06-06 | 1996-06-05 | Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos. |
| ARP960102931A AR003002A1 (es) | 1995-06-06 | 1996-06-05 | Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102930A AR003134A1 (es) | 1995-06-06 | 1996-06-05 | Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0747056B1 (es) |
| JP (1) | JP2001501907A (es) |
| KR (1) | KR19990022497A (es) |
| CN (1) | CN1239429A (es) |
| AR (2) | AR003134A1 (es) |
| AT (1) | ATE187643T1 (es) |
| AU (1) | AU696927B2 (es) |
| BR (1) | BR9608390A (es) |
| CA (1) | CA2223174A1 (es) |
| CO (1) | CO4700447A1 (es) |
| CZ (1) | CZ383097A3 (es) |
| DE (1) | DE69605600T2 (es) |
| DK (1) | DK0747056T3 (es) |
| EA (1) | EA199800014A1 (es) |
| ES (1) | ES2142545T3 (es) |
| GR (1) | GR3032863T3 (es) |
| HU (1) | HUP9900854A3 (es) |
| IL (1) | IL118573A (es) |
| NO (1) | NO975560L (es) |
| PE (1) | PE2298A1 (es) |
| PL (1) | PL323941A1 (es) |
| PT (1) | PT747056E (es) |
| SI (1) | SI0747056T1 (es) |
| TR (1) | TR199701508T1 (es) |
| WO (1) | WO1996039141A1 (es) |
| YU (1) | YU34296A (es) |
| ZA (1) | ZA964681B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0937145A1 (en) * | 1996-11-22 | 1999-08-25 | Akzo Nobel N.V. | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
| US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
| US5393785A (en) * | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| DE4329344A1 (de) * | 1993-08-27 | 1995-03-02 | Schering Ag | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri |
-
1996
- 1996-05-30 DE DE69605600T patent/DE69605600T2/de not_active Expired - Fee Related
- 1996-05-30 AT AT96303874T patent/ATE187643T1/de not_active IP Right Cessation
- 1996-05-30 EP EP96303874A patent/EP0747056B1/en not_active Expired - Lifetime
- 1996-05-30 SI SI9630163T patent/SI0747056T1/xx unknown
- 1996-05-30 DK DK96303874T patent/DK0747056T3/da active
- 1996-05-30 PT PT96303874T patent/PT747056E/pt unknown
- 1996-05-30 ES ES96303874T patent/ES2142545T3/es not_active Expired - Lifetime
- 1996-06-05 PL PL96323941A patent/PL323941A1/xx unknown
- 1996-06-05 AR ARP960102930A patent/AR003134A1/es not_active Application Discontinuation
- 1996-06-05 WO PCT/US1996/008810 patent/WO1996039141A1/en not_active Ceased
- 1996-06-05 BR BR9608390A patent/BR9608390A/pt not_active Application Discontinuation
- 1996-06-05 CN CN96195984A patent/CN1239429A/zh active Pending
- 1996-06-05 HU HU9900854A patent/HUP9900854A3/hu unknown
- 1996-06-05 CO CO96029179A patent/CO4700447A1/es unknown
- 1996-06-05 JP JP09501298A patent/JP2001501907A/ja active Pending
- 1996-06-05 CZ CZ973830A patent/CZ383097A3/cs unknown
- 1996-06-05 AR ARP960102931A patent/AR003002A1/es not_active Application Discontinuation
- 1996-06-05 AU AU59816/96A patent/AU696927B2/en not_active Ceased
- 1996-06-05 ZA ZA9604681A patent/ZA964681B/xx unknown
- 1996-06-05 PE PE1996000409A patent/PE2298A1/es not_active Application Discontinuation
- 1996-06-05 YU YU34296A patent/YU34296A/sr unknown
- 1996-06-05 IL IL11857396A patent/IL118573A/xx not_active IP Right Cessation
- 1996-06-05 TR TR97/01508T patent/TR199701508T1/xx unknown
- 1996-06-05 EA EA199800014A patent/EA199800014A1/ru unknown
- 1996-06-05 CA CA002223174A patent/CA2223174A1/en not_active Abandoned
- 1996-06-05 KR KR1019970708978A patent/KR19990022497A/ko not_active Withdrawn
-
1997
- 1997-12-02 NO NO975560A patent/NO975560L/no unknown
-
2000
- 2000-03-03 GR GR20000400555T patent/GR3032863T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9608390A (pt) | 1999-05-04 |
| HUP9900854A2 (hu) | 1999-08-30 |
| PE2298A1 (es) | 1998-02-28 |
| HUP9900854A3 (en) | 2000-03-28 |
| GR3032863T3 (en) | 2000-07-31 |
| EA199800014A1 (ru) | 1998-06-25 |
| YU34296A (en) | 1999-11-22 |
| JP2001501907A (ja) | 2001-02-13 |
| CZ383097A3 (cs) | 1998-09-16 |
| NO975560D0 (no) | 1997-12-02 |
| TR199701508T1 (xx) | 1998-03-21 |
| AU696927B2 (en) | 1998-09-24 |
| CA2223174A1 (en) | 1996-12-12 |
| EP0747056A2 (en) | 1996-12-11 |
| DK0747056T3 (da) | 2000-05-01 |
| EP0747056B1 (en) | 1999-12-15 |
| DE69605600T2 (de) | 2000-05-31 |
| KR19990022497A (ko) | 1999-03-25 |
| CN1239429A (zh) | 1999-12-22 |
| DE69605600D1 (de) | 2000-01-20 |
| PT747056E (pt) | 2000-05-31 |
| EP0747056A3 (en) | 1997-03-05 |
| WO1996039141A1 (en) | 1996-12-12 |
| CO4700447A1 (es) | 1998-12-29 |
| IL118573A0 (en) | 1996-10-16 |
| ZA964681B (en) | 1997-12-05 |
| ATE187643T1 (de) | 2000-01-15 |
| AR003134A1 (es) | 1998-07-08 |
| NO975560L (no) | 1998-01-26 |
| SI0747056T1 (en) | 2000-06-30 |
| PL323941A1 (en) | 1998-04-27 |
| IL118573A (en) | 2000-01-31 |
| AU5981696A (en) | 1996-12-24 |
| ES2142545T3 (es) | 2000-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR002964A1 (es) | Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento. | |
| UY27740A1 (es) | Nuevos compuestos | |
| AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| ES2114931T3 (es) | Nuevos esteres esteroidales. | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| AR007012A1 (es) | Compuestos de 2-fenil-3-benzoil-benzotiofenos, composiciones farmaceuticas que los contienen y el uso de dichos compuestos para el tratamiento del sindrome postmenopausico, inhibicion del cancer estrogenodependiente, entre otras afecciones patologicas | |
| AR030007A1 (es) | Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR003930A1 (es) | Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados | |
| AR063707A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. | |
| ES2160640T3 (es) | Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos. | |
| MX9202328A (es) | Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo. | |
| ES2523873T3 (es) | Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes | |
| DE69615058D1 (de) | Metalloproteinase inhibitoren | |
| AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas | |
| AR007759A1 (es) | Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden. | |
| AR001931A1 (es) | Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos | |
| TW372969B (en) | Pharmaceutical composition for minimizing bone loss | |
| AR029412A1 (es) | Forma cristalina | |
| AR004777A1 (es) | Uso de derivados de 2-tioxo-imidazolidin-4-ona para la preparacion de medicamentos y medicamentos que los contiene. | |
| AR046874A1 (es) | Nuevos metodos | |
| AR003002A1 (es) | Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones | |
| MX2022011240A (es) | Azálidos de urea inmunomoduladores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |